Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer

American Journal of Translational Research

Volumn 8, Issue 5, 2016, Pages 2255-2264

  Chen, Guanghui ^a   Liang, Yanfang ^b   Guan, Xin ^c   Chen, Hui ^a   Liu, Qiankun ^c   Lin, Bihua ^c   Chen, Can ^b   Huang, Mingyuan ^c   Chen, Jianan ^a   Wu, Weiquan ^c   Liang, Y ^c   Zhou, Keyuan ^c   Zeng, Jincheng ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Taiping People's Hospital of Dongguan)   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; IL 23; IL 27; IL 35; Interleukin (IL) 12

Indexed keywords

CA 125 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPSTEIN BARR VIRUS INDUCED GENE 3 SUBUNIT; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 27; INTERLEUKIN 27P28; INTERLEUKIN 35; KI 67 ANTIGEN; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84971638443     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH and Weiner GJ. AACR Cancer Progress Report 2014. Clin Cancer Res 2014; 20: S1-S112.
2. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G and Hartwell L. The case for early detection. Nat Rev Cancer 2003; 3: 243-252.
3. Goldberg JE and Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010; 11: 1133-1146.
4. DeNardo DG and Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
5. Ahlberg R, MacNamara B, Andersson M, Zheng C, Svensson A, Holm G, Hansson M, Porwit-MacDonald A, Bjorkholm M and Sundblad A. Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-alpha and histamine treatment during remission of non-Hodgkin’s lymphoma. Hematol J 2003; 4: 336-341.
6. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Muller-Holzner E, Daxen-bichler G, Offner FA, Dapunt O and Marth C. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998; 16: 1861-1868.
7. Liu Z, Lee FT, Hanai N, Smyth FE, Burgess AW, Old LJ and Scott AM. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871. Cancer Immun 2002; 2: 13.
8. Tao Q, Pan Y, Wang Y, Wang H, Xiong S, Li Q, Wang J, Tao L, Wang Z, Wu F, Zhang R and Zhai Z. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int J Cancer 2015; 137: 2384-2393.
9. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB and Bar-Sagi D. IL-35 producing B cells promote the development of pancreatic neoplasia. Cancer Discov 2016; 6: 247-255.
10. Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, Herrick EJ, Diaz-Arias A, Moore BJ and Fang Y. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine 2014; 70: 126-133.
11. Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y and Wei XQ. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013; 430: 364-369.
12. Wang Z, Liu J., Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y and Bai XF. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013; 190: 2415-2423.
13. Chen D, Li W, Liu S, Su Y, Han G, Xu C, Liu H, Zheng T, Zhou Y and Mao C. Interleukin-23 promotes the epithelial-mesenchymal transition of oesophageal carcinoma cells via the Wnt/ beta-catenin pathway. Sci Rep 2015; 5: 8604.
14. Yan Q, Su Y, Zhou Y, Zhu H, Yang X amd Xu J. Interleukin-23 strengthens the anti-apoptotic and drug resistance of human tongue squamous cell carcinoma through the Wingless-related integration site/beta-catenin pathway. Hua Xi Kou Qiang Yi Xue Za Zhi 2015; 33: 249-254.
15. Mei Z, Chen S, Chen C, Xiao B, Li F, Wang Y and Tao Z. Interleukin-23 Facilitates Thyroid Cancer Cell Migration and Invasion by Inhibiting SOCS4 Expression via MicroRNA-25. PLoS One 2015; 10: e0139456.
16. Yoshimoto T, Chiba Y, Furusawa J, Xu M, Tsunoda R, Higuchi K and Mizoguchi I. Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci 2015; 106: 1103-1110.
17. Li MS, Liu Z, Liu J., Zhu X, Liu Z and Bai XF. The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy 2015; 7: 191-200.
18. Samy N, Ragab HM, El Maksoud NA and Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark 2010; 6: 63-72.
19. Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, Wang ZY, Wu BH, Chen XD, He L, Zhang S, Wang CY and Xu JF. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013; 6: 1806-1816.
20. Liao KL, Bai XF and Friedman A. Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis. PLoS One 2014; 9: e110126.
21. Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH and Zeng C. IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev 2015; 16: 2845-2849.
22. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J and Yoshimoto T. Regulation of an-titumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010; 2010: 832454.
23. Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, Hu X, Wei L, Hoft DF and Liu J. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol 2013; 190: 5894-5902.
24. Zhang L, Li J, Li L, Zhang J, Wang X, Yang C, Li Y, Lan F and Lin P. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis 2014; 35: 1330-1340.
25. Li J, Zhang L, Zhang J, Wei Y, Li K, Huang L, Zhang S, Gao B, Wang X and Lin P. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis 2013; 34: 658-666.
26. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E and Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008; 9: 650-657.
27. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP and de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957.
28. Zou W and Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248-256.
29. Chan IH, Jain R, Tessmer MS, Gorman D, Mangadu R, Sathe M, Vives F, Moon C, Penaflor E, Turner S, Ayanoglu G, Chang C, Basham B, Mumm JB, Pierce RH, Yearley JH, McClanahan TK, Phillips JH, Cua DJ, Bowman EP, Kastelein RA and LaFace D. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol 2014; 7: 842-856.
30. Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T and Inoue N. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 2008; 180: 7175-7183.
31. Fukuda M, Ehara M, Suzuki S, Ohmori Y and Sakashita H. IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity. Int J Oncol 2010; 36: 1355-1365.
32. Heckel MC, Wolfson A, Slachta CA, Schwarting R, Salgame P, Katsetos CD and Platsoucas CD. Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol 2011; 266: 143-153.
33. Gangemi S, Minciullo P, Adamo B, Franchina T, Ricciardi GR, Ferraro M, Briguglio R, Toscano G, Saitta S and Adamo V. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem 2012; 113: 2122-2125.
34. Jin P, Ren H, Sun W, Xin W, Zhang H and Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol 2014; 75: 29-33.
35. Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L, Guo Y and Fan K. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2015; 36: 2651-2656.
36. Yin Y, Zeng K, Wu M, Ding Y, Zhao M and Chen Q. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer. Cell Biochem Biophys 2014; 70: 1145-1151.
37. Li FY, Wu SG, Zhou J, Sun JY, Lin Q, Lin HX, Guan XX and He ZY. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One 2014; 9: e87264.
38. Chen C, Yuan JP, Wei W, Tu Y, Yao F, Yang XQ, Sun JZ, Sun SR and Li Y. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications. Int J Nanomedicine 2014; 9: 1039-1048.
39. Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, Yang M and Zhang Q. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Target Oncol 2014; 9: 349-357.
40. Wang XF, Wu YH, Wang MS and Wang YS. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev 2014; 15: 363-368.